TILs and PET-CT can predict pCR in HER2-positive metastatic breast cancerJune 2, 2020Breast CancerMetastatic Breast Cancer
Treating primary tumor doesn’t improve OS in stage IV breast cancerJune 1, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Pyrotinib bests lapatinib in HER2+ metastatic breast cancerMay 31, 2020Breast CancerMetastatic Breast CancerASCO Breast Cancer
Expanding the role of PARP inhibitors in breast cancerMay 31, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastasesMay 30, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancerMay 29, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBCMay 28, 2020Breast CancerMetastatic Breast Cancer
Mammography cuts risk for fatal breast cancers: New dataMay 13, 2020Breast CancerPreventive CarePatient & Survivor CareMetastatic Breast Cancer
Novel immune activator boosts immunotherapy benefit in TNBCMay 1, 2020Breast CancerMetastatic Breast Cancer
EMBRACA shows no overall survival benefit with talazoparibApril 29, 2020Breast CancerMetastatic Breast Cancer
Metastatic cancer linked to worse outcomes of COVID-19April 29, 2020Patient & Survivor CareBreast CancerCOVID-19 UpdatesHead & Neck/Thyroid CancersGastroenterologyLung CancerGynecologic Cancer
ESMO gets creative with guidelines for breast cancer care in the COVID-19 eraApril 28, 2020Breast CancerCOVID-19 UpdatesMetastatic Breast Cancer
FDA OKs new drug for triple-negative breast cancerApril 23, 2020Breast CancerMetastatic Breast Cancer
FDA approves first new breast cancer drug with international groupApril 20, 2020Breast CancerMetastatic Breast Cancer
Breast-conserving surgery deemed okay in high-risk hereditary breast cancersApril 15, 2020Breast CancerMetastatic Breast Cancer
